These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21350366)

  • 21. Immunogenicity of Twinrix in older adults: a critical analysis.
    Stoffel M; Lievens M; Dieussaert I; Martin I; André F
    Expert Rev Vaccines; 2003 Feb; 2(1):9-14. PubMed ID: 12901592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Controlled Trial to Evaluate a Potential Hepatitis B Booster Vaccination Strategy Using Combined Hepatitis A and B Vaccine.
    Li F; Hu Y; Zhou Y; Chen L; Xia W; Song Y; Tan Z; Gao L; Yang Z; Zeng G; Han X; Li J; Li J
    Pediatr Infect Dis J; 2017 May; 36(5):e157-e161. PubMed ID: 28060048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine.
    Bolther M; Andersen KLD; Tolstrup M; Visvanathan K; Woolley I; Skinner N; Millen R; Warner N; Østergaard L; Jensen-Fangel S
    Hum Vaccin Immunother; 2018 Jun; 14(6):1483-1488. PubMed ID: 29474139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
    Vesikari T; Langley JM; Segall N; Ward BJ; Cooper C; Poliquin G; Smith B; Gantt S; McElhaney JE; Dionne M; van Damme P; Leroux-Roels I; Leroux-Roels G; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson DE; Popovic V; Diaz-Mitoma F;
    Lancet Infect Dis; 2021 Sep; 21(9):1271-1281. PubMed ID: 33989539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial.
    Chaiwarith R; Praparattanapan J; Kotarathititum W; Wipasa J; Chaiklang K; Supparatpinyo K
    AIDS Res Ther; 2019 Nov; 16(1):33. PubMed ID: 31711528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study.
    Burgess MA; Rodger AJ; Waite SA; Collard F
    Vaccine; 2001 Sep; 19(32):4835-41. PubMed ID: 11535336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine.
    Cardell K; Akerlind B; Sällberg M; Frydén A
    J Infect Dis; 2008 Aug; 198(3):299-304. PubMed ID: 18544037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults.
    Potsch DV; Camacho LA; Tuboi S; Villar LM; Miguel JC; Ginuíno C; Silva EF; Mendonça RM; Moreira RB; Barroso PF
    Vaccine; 2012 Sep; 30(41):5973-7. PubMed ID: 22828589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.
    Van Herck K; Van Damme P; Collard F; Thoelen S
    Scand J Gastroenterol; 1999 Dec; 34(12):1236-40. PubMed ID: 10636072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course.
    Nicolini LA; Magne F; Signori A; Di Biagio A; Sticchi L; Paganino C; Durando P; Viscoli C
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):922-928. PubMed ID: 29926738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody persistence and immune memory 4 years post-vaccination with combined hepatitis A and B vaccine in adults aged over 40 years.
    Chlibek R; von Sonnenburg F; Van Damme P; Smetana J; Tichy P; Gunapalaiah B; Leyssen M; Jacquet JM
    J Travel Med; 2011; 18(2):145-8. PubMed ID: 21366801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects.
    Potsch DV; Oliveira ML; Ginuíno C; Miguel JC; Oliveira SA; Silva EF; Moreira RB; Cruz GV; Oliveira AL; Camacho LA; Barroso PF
    Vaccine; 2010 Feb; 28(6):1447-50. PubMed ID: 19995540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of booster vaccination on combined hepatitis A and hepatitis B vaccine in both anti-HBs and anti-HAV negative children 5-15 years after hepatitis B vaccine primary immunization.
    Chen Y; Gu H; Cheng S; Shen L; Cui F; Wang F; Yao J; Xia S; Lv H; Liang X
    Hum Vaccin Immunother; 2013 Apr; 9(4):898-902. PubMed ID: 23295964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and reactogenicity of a combined high dose hepatitis A and hepatitis B vaccine, compared to that of Twinrix in healthy Indian children.
    Guptan RC; Thakur V; Safary A; Sarin SK
    Vaccine; 2002 May; 20(16):2102-6. PubMed ID: 11972979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix(®) in subjects aged 11-17 years: an open, randomised, controlled trial.
    Østergaard L; Silfverdal SA; Berglund J; Flodmark CE; West C; Bianco V; Baine Y; Miller JM
    Vaccine; 2012 Jan; 30(4):774-83. PubMed ID: 22107850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of revaccination using different schemes among adults with low or undetectable anti-HBs titers after hepatitis B virus vaccination.
    Lin CS; Xie SB; Liu J; Zhao ZX; Chong YT; Gao ZL
    Clin Vaccine Immunol; 2010 Oct; 17(10):1548-51. PubMed ID: 20719983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B revaccination in HIV-infected vaccine non-responders: is double dosing always necessary?
    Chatkittikunwong G; Khawcharoenporn T
    Int J STD AIDS; 2016 Sep; 27(10):850-5. PubMed ID: 26185040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in healthy Chilean subjects.
    Prado V; Riedemann S; Ibarra H; Potin M
    Int J Infect Dis; 2002 Jun; 6(2):129-33. PubMed ID: 12121601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The duration of hepatitis B vaccine immunity in pediatric dialysis patients.
    Sheth RD; Peskin MF; Du XL
    Pediatr Nephrol; 2014 Oct; 29(10):2029-37. PubMed ID: 24839216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.